RESUMEN
Objective To discuss the efficacy and safety of different second-line chemotherapies in small cell lung cancer chemotherapy.Methods 170 patients with small cell lung cancer who were failure to first -line treatment were chosen,they were randomly divided into observation group and control group.The control group was given paclitaxel plus cisplatin second-line chemotherapy,the observation group used the irinotecan joint cisplatin second-line chemotherapy.The effect of the two groups was recorded.Results The effective rate of the observation group was 45.88%,which of the control group was 25.88%,the difference between the two groups was statistically significant (χ2 =7.389,P<0.05).The median survival time,total survival time,median disease-free survival time, Karnofsky score,pain score of the observation group were (10.32 ±2.41)months,(7.89 ±1.88)months,(7.54 ± 1.78)months,(83.23 ±6.89)points,(2.37 ±1.07)points,which of the control group were (7.45 ±1.03)months, (3.16 ±0.79)months,(3.89 ±0.68)months,(69.97 ±2.33)points,(4.81 ±2.13)points,the differences between the two groups were statistically significant (t =10.095,21.384,17.660,21.384,17.660,all P<0.05).In the observation group,nausea and vomiting occurred in 5 cases,thrombocytopenia in 3 cases,anemia in 1 case,leukopenia in 7 cases,hypodynamia in 12 cases.In the control group,nausea and vomiting occurred in 16 cases,thrombocytopenia in 11 cases,6 cases of anemia,leukopenia in 18 patients,hypodynamia in 26 cases,the differences between the two groups were statistically significant(χ2 =6.574,4.981,4.722,4.981,4.722,all P <0.05).Conclusion The second-line chemotherapy regimens with irinotecan used in small cell lung cancer patients can improve the treatment effect,adverse reaction mild,prolong patients'survival,it is worth popularizing in clinical.
RESUMEN
Objective To detect the excision repair cross-complementing gene 1 (ERCC1) and thymidylate of the acid synthase (TS) in non-small cell lung cancer (NSCLC) and its adjacent tissue,and investigate the relationship of the expression of ERCC1 and TS with the clinical characteristics of NSCLC and prognosis for NSCLC individual therapy to provide experimental basis.Methods The protein expression levels of ERCC1 and TS in 50 cases of postoperative NSCLC cancer and adjacent tissue were detected by immunohistochemical method and the relationship among the expression of ERCC1,TS,and overall survival of patients with NSCLC Phase (OS),disease progression time (TTP),the median OS,and median TTP was analyzed.Results (1)There was an obvious difference between the expression of ERCC1,TS in cancer and paraneoplastic tissue of NSCLC,which had statistically significance (64.00％ vs 20.00％,x2 =19.87,P ＜ 0.01 ;48.00％ vs 24.00％,x2 =6.25,P ＜ 0.05) ; (2)The continued investigation in the patients who received postoperative cisplatin or carboplatin chemotherapy showed that the 0S of negative expression of ERCC1 was significantly longer than the positive one (19.10 vs 10.00 months;x2 =8.133,P =0.002),so was median TTP (15.30 vs 9.00 months; x2 =7.410,P =0.003).The median 0S of the negative expression of TS,was significantly longer than the positive one (17.80 vs 11.00 months,x2 =7.001,P =0.008),so was median TTP (11.40 vs 6.80 months; x2 =5.884,P =0.026).Conclusions ERCC1 and TS protein may become sensitive predictors of platinum chemosensitivity for NSCLC patients ; the detection of combined with ERCC1 and TS would contribute to the selection of individualized treatment programs for NSCLC.
RESUMEN
<p><b>BACKGROUND</b>To evaluate and compare the effects and toxicity of the domestic product of recombinant mutant human tumor necrosis factor (rmhTNF) combined with chemotherapy and chemotherapy alone in the treatment of patients with non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>Two hundred patients with NSCLC in multicenter were randomly devided into trial group (150 cases) and control group (50 cases). Chemotherapy with CAP regimen was given to the patients. Meanwhile, rmhTNF injection of 4×10⁶U/m² was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy cycle in the trial group. The control patients received chemotherapy alone. Twenty-one days were as a cycle, 2 cycles were given to each patient. The chemotherapeutic effects and toxicity were observed and compared between the two groups after the therapy.</p><p><b>RESULTS</b>of the 200 patients, 5 cases in the trial group and 3 cases in the control group were out of the trial because of economy. The other 192 cases (145 cases in the trial group and 47 cases in the control group) could be analyzed and evaluated the clinical effects and toxicity. The response rate of chemotherapy was 46.90% (68/145) in the trial group and 17.02% (8/47) in the control group respectively ( P =0.001). The KPS scores was 86.02±9.74 in the trial group, and 80.14±9.10 in the control group ( P =0.025). No significant difference of degree III+IV toxicity was observed between the two groups ( P > 0.05). The side effects related to rmhTNF included slight fever, cold-like symptoms, pain and red and swelling in the injection site. All of them were mild and didn't need any treatment and disappeared after the therapy. There were no severe abnormality of liver and kidney function and ECG in both groups.</p><p><b>CONCLUSIONS</b>The results demonstrate that the effects of domestic rmhTNF combined with chemotherapy are remarkably higher than that of chemotherapy alone in the treatment of NSCLC. rmhTNF can increase the sensitivity to chemotherapy and improve the quality of life of the patients with slight toxicity. Hence rmhTNF is worth expanding clinical use.</p>
RESUMEN
Purpose:To evaluate the Application of Ultrasound Guided Mammotome Minimallay Invasive Biopsy System in diagnosis and treatment of breast masses. Methods:68 breast lesions in 42 patients were performed by Ultrasound Guided Mammotome Minimallay Invasive Biopsy System in order to evaluateits diagnostic and therapeutic ifficacy. Results:40 lesions were diagnosed as fibroadenoma , 19 lesions as fibroadenomatoid hyperplasia, 7 lesions as breast adenosis,2 lesions diagnosed as galactocele in operation but fibre and fat tissue after operation by pathology. 67 lesions were excised by mammotome system. 1 lesion was stopped duete hmorrage,1 case had serious hematoma. 1 case had machine failure but was resolved. The excision times were on the average 28 in every lesion,the lengh of incision is only 3mm,and the duration of operation was 30 minutes. No evidence of recurrence was found by physical examination and the ultrasound evaluation during the follow up 1~6 monthes. Conclusions:Ultrasound guided mammotome minimallay invasive biopsy system excision for benign breast mass was complete and the postoperative breast appearance was satisfactory.
RESUMEN
Objective To improve the existing folded grid tent and enhance the efficiency of medical support.Methods The simple pulley and handling dolly were developed,and the skeleton rod was strengthened.Results The improved folded grid tent was easy to carry,transport and handle,and the skeleton rod was solid enough.Conclusion The improved folded grid tent is gifted with an enhanced support efficiency and a longer service time.